TRVI Stock Forecast & Price Target

Trevi Therapeutics is a clinical-stage biopharmaceutical company that specializes in developing and commercializing an investigational therapy called Haduvio for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. With a strong IP, increasing enthusiasm for Haduvio amongst specialists, and no other therapies in active development for IPF-related cough, TRVI is well-positioned to emerge as a best-in-class and first-in-class therapy with a significant market opportunity. The recent discontinuation of a competitor's therapy in RCC, coupled with robust patent protection and clinical and commercial risk mitigation strategies, reinforces my positive outlook for TRVI.

Trevi Therapeutics is a clinical-stage biopharmaceutical company that is focused on developing an oral extended-release formulation of nalbuphine called Haduvio for the treatment of chronic cough. Despite the recent increases in stock price, investors are missing the potential value of Haduvio, as GSK and MRK have both failed in the same space, leaving a vacuum for a promising asset. Additionally, the company has a differentiated approach with its Matrix-M ingredient, which may appeal to elderly patients who may have difficulty tolerating other treatments.